How do I buy Disc Medicine, Inc. Common Stock (IRON) stock?

Buying Disc Medicine, Inc. Common Stock (IRON) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "IRON", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy IRON by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for IRON on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Disc Medicine, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Disc Medicine, Inc. Common Stock (IRON) pay dividends?

At the moment, Disc Medicine, Inc. Common Stock (IRON) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track IRON's performance via the price chart in the Gotrade app.

Is buying IRON on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy IRON?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if IRON is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Disc Medicine, Inc. Common Stock (IRON) Stock Price: Nov 11 Close $87.08

News tone: automated (AI) classification of the article's content, not a price prediction.

About Disc Medicine, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees165

CEODr. John D. Quisel Esq., J.D., Ph.D.

IPO DateAug 12, 2020

HeadquartersWatertown, MA

Key Executives

Name	Title	Year Born
Dr. John D. Quisel Esq., J.D., Ph.D.	CEO, President & Director	1971
Dr. Donald William Nicholson Ph.D.	Executive Chairman	1958
Dr. Brian MacDonald ChB, MB, Ph.D.	Founder & Chair of Scientific Advisory Board	1961
Ms. Jean M. Franchi CPA	Chief Financial Officer	1966
Mr. Jonathan Yu M.B.A.	Chief Opearating Officer	1981
Dr. William Jacob Savage M.D., Ph.D.	Chief Medical Officer	1974
Ms. Pamela Stephenson M.P.H.	Chief Commercial Officer	1968
Dr. Rahul Rajan Kaushik Ph.D.	Chief Technical Officer	—
Dr. Rahul Khara J.D., Pharm.D.	Chief Legal Officer & Secretary	1982
Ms. Lisa Amaya Price	Chief Human Resources Officer	—

Fundamentals

Valuation

Price-to-book value6.38

Profitability

Return on Equity-37.00%

Return on Assets-34.00%

EBITDA$-241.16M

Trading

Average volume1,590,974

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 66.93
MACD 12/26/9: 4.05
EMA 9 of MACD: 3.44
MACD histogram: 0.61
SMA 50: $71.52; Price above SMA 50
EMA 50: $74.42; Price above EMA 50
SMA 200: $70.93; Price above SMA 200
EMA 200: $73.40; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

8 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $92.00
Average: $123.75
High: $170.00

Morgan Stanley

Sean Laaman

Buy

Target price

$92.00

HC Wainwright & Co.

Douglas Tsao

Buy

Target price

$127.00

Wells Fargo

Derek Archila

Buy

Target price

$124.00

BMO Capital

Evan David Seigerman

Buy

Target price

$120.00

Truist Securities

Danielle Brill

Buy

Target price

$115.00

Wedbush

David Nierengarten

Buy

Target price

$110.00

Guggenheim

Debjit Chattopadhyay

Buy

Target price

$132.00

Cantor Fitzgerald

Kristen Kluska

Buy

Target price

$170.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2022												+0.0
2023	+22.6	+20.9	-15.7	+49.3	+7.3	+11.7	+12.3	+5.1	-10.5	+0.4	+20.0	+3.6
2024	+10.1	+1.5	-17.3	-18.6	+19.0	+24.3	-7.1	+17.4	-0.9	-15.0	+34.6	-1.3
2025	-10.6	+2.2	-8.6	+4.8	-6.0	+11.0	+16.9	+1.2	+7.6	+28.6	+10.2	-13.4
2026	-2.2	-17.4	-3.9	+1.8	+4.0	+1.6	+2.7	+3.1	-16.8	+27.1	+10.8

Compare stocks

IRON

Buy IRON

Market cap

$3.97B

-

Price / Earnings ratio

-15.90

-

Price / Sales ratio

-

Dividend yield

0.00%

-

Average volume

1,590,974

-

Earnings per share

$-6.34

-

Disc Medicine, Inc. Common Stock (IRON) Stock

Key stats

Compare with IRON

Recent news

Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission

Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission

Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints

Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints

Disc Medicine's rare disease drug succeeds in late-stage trial

Disc Medicine's rare disease drug succeeds in late-stage trial

Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges

Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission

Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission

Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints

Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints

Disc Medicine's rare disease drug succeeds in late-stage trial

Disc Medicine's rare disease drug succeeds in late-stage trial

Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges

Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges

Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge

Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON

IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm

IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm

Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection

Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst

About Disc Medicine, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade